SEC EDGARJUN 51 min read$INSM

Flammer Martina M.D. sold $455K of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 4,424 shares of INSMED Inc (INSM) at an average of $102.90 ($102.27–$103.78, $0.46M total) across 2 trades over 2026-06-03 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Flammer Martina M.D.

Published Jun 5, 2026, 8:11 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate market impact.

Market read

Routine insider sale with modest size; limited trading relevance.

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filings provide transparent disclosure of insider transactions, used by traders to gauge insider sentiment.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

Chief Medical Officer sold 4,424 shares for $455K via 10b5‑1 plan, reducing her stake to 60,486 shares.

Expected impact

likely modest pressure as market prices in the sale

Evidence & confidence

Sale size is modest relative to float and disclosed via pre‑arranged plan; no new corporate event accompanies it.

Market effects

Sector

Minimal impact on biotech/medical device sector; typical insider sales are routine.

Regional

US market only; no broader regional effect.

Global

Low relevance globally.

Counterpoint

What could challenge this read

The sale could be a red flag if the insider anticipates upcoming challenges.

Key entities

Insider
Flammer Martina M.D.
Chief Medical Officer of INSMED Inc.

Read at source ← All news

OCT 22

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

ajmc.com3 min

OCT 20

$INSMLow

Insmed Appoints Former Sanofi CEO Paul Hudson and Utpal Koppikar to Board

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

citybiz.co2 min

OCT 19

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

investing.com1 min

OCT 19

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

stocktitan.net2 min

OCT 15

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

investing.com2 min

OCT 14